tradingkey.logo

Journey Medical Corp

DERM
8.350USD
0.0000.00%
Handelsschluss 02/06, 16:00ETKurse um 15 Minuten verzögert
220.21MMarktkapitalisierung
VerlustKGV TTM

Journey Medical Corp

8.350
0.0000.00%

mehr Informationen über Journey Medical Corp Unternehmen

Journey Medical Corporation is a commercial-stage pharmaceutical company. The Company is focused on selling and marketing of the United States Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products, which have been approved FDA for sale in the United States, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox, and Luxamend. Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis. Accutane is an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne. Targadox is an oral doxycycline drug for adjunctive therapy for severe acne. Luxamend is a water-based emulsion formulated to provide moist healing environment.

Journey Medical Corp Informationen

BörsenkürzelDERM
Name des UnternehmensJourney Medical Corp
IPO-datumNov 12, 2021
CEOMaraoui (Claude)
Anzahl der mitarbeiter41
WertpapierartOrdinary Share
GeschäftsjahresendeNov 12
Addresse9237 E Via De Ventura Blvd., Suite 105
StadtSCOTTSDALE
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl85258
Telefon14804346670
Websitehttps://journeymedicalcorp.com/
BörsenkürzelDERM
IPO-datumNov 12, 2021
CEOMaraoui (Claude)

Führungskräfte von Journey Medical Corp

Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Claude Maraoui
Mr. Claude Maraoui
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.06M
+1239123.00%
Dr. Lindsay A. Rosenwald, M.D.
Dr. Lindsay A. Rosenwald, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
377.89K
+50000.00%
Mr. Ramsey Alloush
Mr. Ramsey Alloush
Chief Operating Officer, General Counsel
Chief Operating Officer, General Counsel
316.68K
+46863.00%
Mr. Joseph Benesch, CPA
Mr. Joseph Benesch, CPA
Chief Financial Officer, Corporate Controller
Chief Financial Officer, Corporate Controller
100.78K
+28907.00%
Mr. Neil Herskowitz
Mr. Neil Herskowitz
Independent Director
Independent Director
98.89K
+20000.00%
Ms. Miranda Jayne Toledano
Ms. Miranda Jayne Toledano
Independent Director
Independent Director
98.89K
+20000.00%
Mr. Michael C. Pearce
Mr. Michael C. Pearce
Independent Director
Independent Director
57.17K
+20000.00%
Mr. Justin Smith
Mr. Justin Smith
Independent Director
Independent Director
--
--
Ms. Jaclyn Jaffe
Ms. Jaclyn Jaffe
Investor Relations
Investor Relations
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Claude Maraoui
Mr. Claude Maraoui
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.06M
+1239123.00%
Dr. Lindsay A. Rosenwald, M.D.
Dr. Lindsay A. Rosenwald, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
377.89K
+50000.00%
Mr. Ramsey Alloush
Mr. Ramsey Alloush
Chief Operating Officer, General Counsel
Chief Operating Officer, General Counsel
316.68K
+46863.00%
Mr. Joseph Benesch, CPA
Mr. Joseph Benesch, CPA
Chief Financial Officer, Corporate Controller
Chief Financial Officer, Corporate Controller
100.78K
+28907.00%
Mr. Neil Herskowitz
Mr. Neil Herskowitz
Independent Director
Independent Director
98.89K
+20000.00%
Ms. Miranda Jayne Toledano
Ms. Miranda Jayne Toledano
Independent Director
Independent Director
98.89K
+20000.00%

Umsatzaufteilung

Währung: USDAktualisiert: Tue, Jan 6
Währung: USDAktualisiert: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Qbrexa
7.36M
43.23%
Emrosi
4.88M
28.68%
Accutane
2.77M
16.26%
Amzeeq
1.31M
7.71%
Other branded revenue
702.00K
4.12%
Nach RegionUSD
Name
Umsatz
Anteil
United States
17.63M
0.00%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Qbrexa
7.36M
43.23%
Emrosi
4.88M
28.68%
Accutane
2.77M
16.26%
Amzeeq
1.31M
7.71%
Other branded revenue
702.00K
4.12%

Aktionärsstatistik

Aktualisiert: Sat, Jan 31
Aktualisiert: Sat, Jan 31
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Fortress Biotech Inc
12.33%
Maraoui (Claude)
7.56%
Tang Capital Management, LLC
6.80%
Wasatch Global Investors Inc
4.79%
Opaleye Management Inc.
3.56%
Andere
64.95%
Aktionäre
Aktionäre
Anteil
Fortress Biotech Inc
12.33%
Maraoui (Claude)
7.56%
Tang Capital Management, LLC
6.80%
Wasatch Global Investors Inc
4.79%
Opaleye Management Inc.
3.56%
Andere
64.95%
Aktionärstypen
Aktionäre
Anteil
Corporation
12.33%
Individual Investor
12.01%
Hedge Fund
11.42%
Investment Advisor
10.16%
Investment Advisor/Hedge Fund
9.10%
Private Equity
0.84%
Insurance Company
0.66%
Research Firm
0.31%
Pension Fund
0.15%
Andere
43.02%

Institutionelle Beteiligung

Aktualisiert: Mon, Dec 8
Aktualisiert: Mon, Dec 8
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
111
6.92M
29.29%
--
2025Q3
113
6.92M
33.12%
+300.88K
2025Q2
111
6.62M
36.44%
+1.49M
2025Q1
80
5.12M
29.92%
+3.29K
2024Q4
74
3.80M
30.46%
+100.75K
2024Q3
75
2.18M
26.36%
-187.63K
2024Q2
70
2.37M
22.85%
+547.02K
2024Q1
61
1.83M
18.72%
-778.53K
2023Q4
59
1.36M
20.20%
-795.63K
2023Q3
44
2.15M
17.23%
+484.38K
Mehr Anzeigen

Aktionärsaktivitäten

Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Fortress Biotech Inc
3.36M
15.9%
--
--
Apr 14, 2025
Maraoui (Claude)
2.06M
9.75%
+1.24M
+150.79%
Aug 25, 2025
Tang Capital Management, LLC
1.85M
8.77%
--
--
Sep 30, 2025
Wasatch Global Investors Inc
1.31M
6.18%
+154.21K
+13.39%
Sep 30, 2025
Opaleye Management Inc.
971.06K
4.59%
+876.06K
+922.17%
Sep 30, 2025
The Vanguard Group, Inc.
615.23K
2.91%
+50.24K
+8.89%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
571.92K
2.71%
+91.62K
+19.08%
Sep 30, 2025
Summit Financial, LLC
379.83K
1.8%
+379.83K
--
Sep 30, 2025
Rosenwald (Lindsay A)
377.89K
1.79%
+50.00K
+15.25%
Aug 05, 2025
Essex Investment Management Company, LLC
354.02K
1.68%
+125.82K
+55.13%
Sep 30, 2025
Mehr Anzeigen

Verbundene ETFs

Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
iShares Micro-Cap ETF
0.02%
iShares Russell 2000 Growth ETF
0.01%
Global X Russell 2000 ETF
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Dimensional US Core Equity 1 ETF
0%
ProShares UltraPro Russell2000
0%
Royce Quant Small-Cap Quality Value ETF
0%
Proshares Ultra Russell 2000
0%
iShares Micro-Cap ETF
Anteil0.02%
iShares Russell 2000 Growth ETF
Anteil0.01%
Global X Russell 2000 ETF
Anteil0%
ProShares Hedge Replication ETF
Anteil0%
iShares Russell 2000 ETF
Anteil0%
DFA Dimensional US Sustainability Core 1 ETF
Anteil0%
Dimensional US Core Equity 1 ETF
Anteil0%
ProShares UltraPro Russell2000
Anteil0%
Royce Quant Small-Cap Quality Value ETF
Anteil0%
Proshares Ultra Russell 2000
Anteil0%

Dividende

In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten

Aktien-Split

Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
KeyAI